Publication:
New Therapeutic Approaches for Allergy: A Review of Cell Therapy and Bio- or Nano-Material-Based Strategies

dc.contributor.authorParis, Juan L.
dc.contributor.authorde la Torre, Paz
dc.contributor.authorFlores, Ana I.
dc.contributor.authoraffiliation[Paris,JL] Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain. [Paris,JL] Andalusian Centre for Nanomedicine and Biotechnology-BIONAND, Málaga, Spain. [de la Torre,P; Flores,AI] Grupo de Medicina Regenerativa, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
dc.date.accessioned2024-02-19T15:32:22Z
dc.date.available2024-02-19T15:32:22Z
dc.date.issued2021-12-14
dc.description.abstractAllergy constitutes a major health issue due to its large prevalence. The established therapeutic approaches (allergen avoidance, antihistamines, and corticosteroids) do not address the underlying causes of the pathology, highlighting the need for other long-term treatment options. Antigen-specific immunotherapy enables the long-term control of allergic diseases by promoting immunological tolerance to the allergen. However, efficacious immunotherapies are not available for all possible allergens, and the risk of undesired reactions during therapy remains a concern, especially in patients with severe allergic reactions. In this context, two types of therapeutic strategies appear especially promising for the future in the context of allergy: cell therapy and bio- or nano-material-based therapy. In this review, the main strategies developed this far in these two types of strategies are discussed, with several examples illustrating the different approaches.
dc.description.sponsorshipThis work was funded by Instituto de Salud Carlos III (ISCIII), Ministry of Economy, Industry, and Competitiveness, co-funded by the European Regional Development Fund, grants number PI18/01278; and PI 20/012 by Fundacion Francisco Soria Melguizo. J.L.P holds a “Sara Borrell” fellowship (CD19/00250) from ISCIII, co-funded by the European Social Fund (“El FSE invierte en futuro”).
dc.identifier.doi10.3390/pharmaceutics13122149
dc.identifier.e-issn1999-4923es_ES
dc.identifier.journalPharmaceuticses_ES
dc.identifier.otherhttp://hdl.handle.net/10668/4125
dc.identifier.pubmedID34959429es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18519
dc.language.isoeng
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/13/12/2149es
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAllergy
dc.subjectCell therapy
dc.subjectBiomaterials
dc.subjectNano-materials
dc.subjectImmunotherapy
dc.subjectAlergia e inmunología
dc.subjectTratamiento basado en trasplante de células y tejidos
dc.subjectMateriales biocompatibles
dc.subjectNanoestructuras
dc.subjectInmunoterapia
dc.subject.meshHumans
dc.subject.meshPrevalence
dc.subject.meshAllergens
dc.subject.meshAdrenal Cortex Hormones
dc.subject.meshHistamine Antagonists
dc.titleNew Therapeutic Approaches for Allergy: A Review of Cell Therapy and Bio- or Nano-Material-Based Strategies
dc.typereview article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isPublisherOfPublication30293a55-0e53-431f-ae8c-14ab01127be9
relation.isPublisherOfPublication.latestForDiscovery30293a55-0e53-431f-ae8c-14ab01127be9

Files